The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Drugs for Central Nervous System Diseases Market Research Report 2025
Synopsis
A drug used to treat neurological diseases that affect the functioning of the brain or spinal cord in the central nervous system
The global Drugs for Central Nervous System Diseases market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Drugs for Central Nervous System Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Central Nervous System Diseases.
Report Scope
The Drugs for Central Nervous System Diseases market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Central Nervous System Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Central Nervous System Diseases companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alkermes
Astrazeneca
Biogen
Bristol Myers Squibb
Lilly
GSK
Merck
Sunovion Pharmaceuticals
Pfizer
Teva
Norvatis
Segment by Type
Antidepressants
Anxiolytics
Anti-manic
Other
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Central Nervous System Diseases companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
A drug used to treat neurological diseases that affect the functioning of the brain or spinal cord in the central nervous system
The global Drugs for Central Nervous System Diseases market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Drugs for Central Nervous System Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Central Nervous System Diseases.
Report Scope
The Drugs for Central Nervous System Diseases market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Central Nervous System Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Central Nervous System Diseases companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alkermes
Astrazeneca
Biogen
Bristol Myers Squibb
Lilly
GSK
Merck
Sunovion Pharmaceuticals
Pfizer
Teva
Norvatis
Segment by Type
Antidepressants
Anxiolytics
Anti-manic
Other
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Central Nervous System Diseases companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Central Nervous System Diseases Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antidepressants
1.2.3 Anxiolytics
1.2.4 Anti-manic
1.2.5 Other
1.3 Market by Application
1.3.1 Global Drugs for Central Nervous System Diseases Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Central Nervous System Diseases Market Perspective (2019-2030)
2.2 Drugs for Central Nervous System Diseases Growth Trends by Region
2.2.1 Global Drugs for Central Nervous System Diseases Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Drugs for Central Nervous System Diseases Historic Market Size by Region (2019-2024)
2.2.3 Drugs for Central Nervous System Diseases Forecasted Market Size by Region (2025-2030)
2.3 Drugs for Central Nervous System Diseases Market Dynamics
2.3.1 Drugs for Central Nervous System Diseases Industry Trends
2.3.2 Drugs for Central Nervous System Diseases Market Drivers
2.3.3 Drugs for Central Nervous System Diseases Market Challenges
2.3.4 Drugs for Central Nervous System Diseases Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Central Nervous System Diseases Players by Revenue
3.1.1 Global Top Drugs for Central Nervous System Diseases Players by Revenue (2019-2024)
3.1.2 Global Drugs for Central Nervous System Diseases Revenue Market Share by Players (2019-2024)
3.2 Global Drugs for Central Nervous System Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs for Central Nervous System Diseases Revenue
3.4 Global Drugs for Central Nervous System Diseases Market Concentration Ratio
3.4.1 Global Drugs for Central Nervous System Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Central Nervous System Diseases Revenue in 2023
3.5 Drugs for Central Nervous System Diseases Key Players Head office and Area Served
3.6 Key Players Drugs for Central Nervous System Diseases Product Solution and Service
3.7 Date of Enter into Drugs for Central Nervous System Diseases Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Central Nervous System Diseases Breakdown Data by Type
4.1 Global Drugs for Central Nervous System Diseases Historic Market Size by Type (2019-2024)
4.2 Global Drugs for Central Nervous System Diseases Forecasted Market Size by Type (2025-2030)
5 Drugs for Central Nervous System Diseases Breakdown Data by Application
5.1 Global Drugs for Central Nervous System Diseases Historic Market Size by Application (2019-2024)
5.2 Global Drugs for Central Nervous System Diseases Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Drugs for Central Nervous System Diseases Market Size (2019-2030)
6.2 North America Drugs for Central Nervous System Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Drugs for Central Nervous System Diseases Market Size by Country (2019-2024)
6.4 North America Drugs for Central Nervous System Diseases Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs for Central Nervous System Diseases Market Size (2019-2030)
7.2 Europe Drugs for Central Nervous System Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Drugs for Central Nervous System Diseases Market Size by Country (2019-2024)
7.4 Europe Drugs for Central Nervous System Diseases Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Central Nervous System Diseases Market Size (2019-2030)
8.2 Asia-Pacific Drugs for Central Nervous System Diseases Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Region (2019-2024)
8.4 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs for Central Nervous System Diseases Market Size (2019-2030)
9.2 Latin America Drugs for Central Nervous System Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Drugs for Central Nervous System Diseases Market Size by Country (2019-2024)
9.4 Latin America Drugs for Central Nervous System Diseases Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Central Nervous System Diseases Market Size (2019-2030)
10.2 Middle East & Africa Drugs for Central Nervous System Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Country (2019-2024)
10.4 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alkermes
11.1.1 Alkermes Company Detail
11.1.2 Alkermes Business Overview
11.1.3 Alkermes Drugs for Central Nervous System Diseases Introduction
11.1.4 Alkermes Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)
11.1.5 Alkermes Recent Development
11.2 Astrazeneca
11.2.1 Astrazeneca Company Detail
11.2.2 Astrazeneca Business Overview
11.2.3 Astrazeneca Drugs for Central Nervous System Diseases Introduction
11.2.4 Astrazeneca Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)
11.2.5 Astrazeneca Recent Development
11.3 Biogen
11.3.1 Biogen Company Detail
11.3.2 Biogen Business Overview
11.3.3 Biogen Drugs for Central Nervous System Diseases Introduction
11.3.4 Biogen Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)
11.3.5 Biogen Recent Development
11.4 Bristol Myers Squibb
11.4.1 Bristol Myers Squibb Company Detail
11.4.2 Bristol Myers Squibb Business Overview
11.4.3 Bristol Myers Squibb Drugs for Central Nervous System Diseases Introduction
11.4.4 Bristol Myers Squibb Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)
11.4.5 Bristol Myers Squibb Recent Development
11.5 Lilly
11.5.1 Lilly Company Detail
11.5.2 Lilly Business Overview
11.5.3 Lilly Drugs for Central Nervous System Diseases Introduction
11.5.4 Lilly Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)
11.5.5 Lilly Recent Development
11.6 GSK
11.6.1 GSK Company Detail
11.6.2 GSK Business Overview
11.6.3 GSK Drugs for Central Nervous System Diseases Introduction
11.6.4 GSK Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)
11.6.5 GSK Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Drugs for Central Nervous System Diseases Introduction
11.7.4 Merck Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)
11.7.5 Merck Recent Development
11.8 Sunovion Pharmaceuticals
11.8.1 Sunovion Pharmaceuticals Company Detail
11.8.2 Sunovion Pharmaceuticals Business Overview
11.8.3 Sunovion Pharmaceuticals Drugs for Central Nervous System Diseases Introduction
11.8.4 Sunovion Pharmaceuticals Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)
11.8.5 Sunovion Pharmaceuticals Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Drugs for Central Nervous System Diseases Introduction
11.9.4 Pfizer Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)
11.9.5 Pfizer Recent Development
11.10 Teva
11.10.1 Teva Company Detail
11.10.2 Teva Business Overview
11.10.3 Teva Drugs for Central Nervous System Diseases Introduction
11.10.4 Teva Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)
11.10.5 Teva Recent Development
11.11 Norvatis
11.11.1 Norvatis Company Detail
11.11.2 Norvatis Business Overview
11.11.3 Norvatis Drugs for Central Nervous System Diseases Introduction
11.11.4 Norvatis Revenue in Drugs for Central Nervous System Diseases Business (2019-2024)
11.11.5 Norvatis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Drugs for Central Nervous System Diseases Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Antidepressants
Table 3. Key Players of Anxiolytics
Table 4. Key Players of Anti-manic
Table 5. Key Players of Other
Table 6. Global Drugs for Central Nervous System Diseases Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Drugs for Central Nervous System Diseases Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Drugs for Central Nervous System Diseases Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Drugs for Central Nervous System Diseases Market Share by Region (2019-2024)
Table 10. Global Drugs for Central Nervous System Diseases Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Drugs for Central Nervous System Diseases Market Share by Region (2025-2030)
Table 12. Drugs for Central Nervous System Diseases Market Trends
Table 13. Drugs for Central Nervous System Diseases Market Drivers
Table 14. Drugs for Central Nervous System Diseases Market Challenges
Table 15. Drugs for Central Nervous System Diseases Market Restraints
Table 16. Global Drugs for Central Nervous System Diseases Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Drugs for Central Nervous System Diseases Market Share by Players (2019-2024)
Table 18. Global Top Drugs for Central Nervous System Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Central Nervous System Diseases as of 2023)
Table 19. Ranking of Global Top Drugs for Central Nervous System Diseases Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Drugs for Central Nervous System Diseases Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Drugs for Central Nervous System Diseases Product Solution and Service
Table 23. Date of Enter into Drugs for Central Nervous System Diseases Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Drugs for Central Nervous System Diseases Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Drugs for Central Nervous System Diseases Revenue Market Share by Type (2019-2024)
Table 27. Global Drugs for Central Nervous System Diseases Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Drugs for Central Nervous System Diseases Revenue Market Share by Type (2025-2030)
Table 29. Global Drugs for Central Nervous System Diseases Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Drugs for Central Nervous System Diseases Revenue Market Share by Application (2019-2024)
Table 31. Global Drugs for Central Nervous System Diseases Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Drugs for Central Nervous System Diseases Revenue Market Share by Application (2025-2030)
Table 33. North America Drugs for Central Nervous System Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Drugs for Central Nervous System Diseases Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Drugs for Central Nervous System Diseases Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Drugs for Central Nervous System Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Drugs for Central Nervous System Diseases Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Drugs for Central Nervous System Diseases Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Drugs for Central Nervous System Diseases Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Drugs for Central Nervous System Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Drugs for Central Nervous System Diseases Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Drugs for Central Nervous System Diseases Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Drugs for Central Nervous System Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Country (2025-2030) & (US$ Million)
Table 48. Alkermes Company Detail
Table 49. Alkermes Business Overview
Table 50. Alkermes Drugs for Central Nervous System Diseases Product
Table 51. Alkermes Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)
Table 52. Alkermes Recent Development
Table 53. Astrazeneca Company Detail
Table 54. Astrazeneca Business Overview
Table 55. Astrazeneca Drugs for Central Nervous System Diseases Product
Table 56. Astrazeneca Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)
Table 57. Astrazeneca Recent Development
Table 58. Biogen Company Detail
Table 59. Biogen Business Overview
Table 60. Biogen Drugs for Central Nervous System Diseases Product
Table 61. Biogen Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)
Table 62. Biogen Recent Development
Table 63. Bristol Myers Squibb Company Detail
Table 64. Bristol Myers Squibb Business Overview
Table 65. Bristol Myers Squibb Drugs for Central Nervous System Diseases Product
Table 66. Bristol Myers Squibb Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)
Table 67. Bristol Myers Squibb Recent Development
Table 68. Lilly Company Detail
Table 69. Lilly Business Overview
Table 70. Lilly Drugs for Central Nervous System Diseases Product
Table 71. Lilly Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)
Table 72. Lilly Recent Development
Table 73. GSK Company Detail
Table 74. GSK Business Overview
Table 75. GSK Drugs for Central Nervous System Diseases Product
Table 76. GSK Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)
Table 77. GSK Recent Development
Table 78. Merck Company Detail
Table 79. Merck Business Overview
Table 80. Merck Drugs for Central Nervous System Diseases Product
Table 81. Merck Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)
Table 82. Merck Recent Development
Table 83. Sunovion Pharmaceuticals Company Detail
Table 84. Sunovion Pharmaceuticals Business Overview
Table 85. Sunovion Pharmaceuticals Drugs for Central Nervous System Diseases Product
Table 86. Sunovion Pharmaceuticals Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)
Table 87. Sunovion Pharmaceuticals Recent Development
Table 88. Pfizer Company Detail
Table 89. Pfizer Business Overview
Table 90. Pfizer Drugs for Central Nervous System Diseases Product
Table 91. Pfizer Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)
Table 92. Pfizer Recent Development
Table 93. Teva Company Detail
Table 94. Teva Business Overview
Table 95. Teva Drugs for Central Nervous System Diseases Product
Table 96. Teva Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)
Table 97. Teva Recent Development
Table 98. Norvatis Company Detail
Table 99. Norvatis Business Overview
Table 100. Norvatis Drugs for Central Nervous System Diseases Product
Table 101. Norvatis Revenue in Drugs for Central Nervous System Diseases Business (2019-2024) & (US$ Million)
Table 102. Norvatis Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Drugs for Central Nervous System Diseases Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Drugs for Central Nervous System Diseases Market Share by Type: 2023 VS 2030
Figure 3. Antidepressants Features
Figure 4. Anxiolytics Features
Figure 5. Anti-manic Features
Figure 6. Other Features
Figure 7. Global Drugs for Central Nervous System Diseases Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Drugs for Central Nervous System Diseases Market Share by Application: 2023 VS 2030
Figure 9. Hospital Pharmacies Case Studies
Figure 10. Retail Pharmacies Case Studies
Figure 11. Online Pharmacies Case Studies
Figure 12. Drugs for Central Nervous System Diseases Report Years Considered
Figure 13. Global Drugs for Central Nervous System Diseases Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Drugs for Central Nervous System Diseases Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Drugs for Central Nervous System Diseases Market Share by Region: 2023 VS 2030
Figure 16. Global Drugs for Central Nervous System Diseases Market Share by Players in 2023
Figure 17. Global Top Drugs for Central Nervous System Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Central Nervous System Diseases as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Drugs for Central Nervous System Diseases Revenue in 2023
Figure 19. North America Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Drugs for Central Nervous System Diseases Market Share by Country (2019-2030)
Figure 21. United States Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Drugs for Central Nervous System Diseases Market Share by Country (2019-2030)
Figure 25. Germany Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Drugs for Central Nervous System Diseases Market Share by Region (2019-2030)
Figure 33. China Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Drugs for Central Nervous System Diseases Market Share by Country (2019-2030)
Figure 41. Mexico Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Drugs for Central Nervous System Diseases Market Share by Country (2019-2030)
Figure 45. Turkey Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Drugs for Central Nervous System Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Alkermes Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)
Figure 48. Astrazeneca Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)
Figure 49. Biogen Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)
Figure 50. Bristol Myers Squibb Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)
Figure 51. Lilly Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)
Figure 52. GSK Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)
Figure 53. Merck Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)
Figure 54. Sunovion Pharmaceuticals Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)
Figure 55. Pfizer Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)
Figure 56. Teva Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)
Figure 57. Norvatis Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
